Our group has developed highly sensitive and specific assays for the detection of PIK3CA hotspot mutations (E545K, H1047R)30–32 and ESR1 mutations33 in EpCAM(+) CTC of early and metastatic breast cancer patients. This evidence concerns the gene EPCAM and breast carcinoma.